Compare PCRX & LXU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | LXU |
|---|---|---|
| Founded | 2006 | 1968 |
| Country | United States | United States |
| Employees | N/A | 513 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2010 | 2006 |
| Metric | PCRX | LXU |
|---|---|---|
| Price | $23.53 | $13.32 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $30.25 | $14.63 |
| AVG Volume (30 Days) | 527.9K | ★ 1.1M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 107.44 | ★ 225.93 |
| EPS | 0.07 | ★ 0.27 |
| Revenue | $541,533,000.00 | ★ $615,208,000.00 |
| Revenue This Year | $6.78 | $13.69 |
| Revenue Next Year | $8.54 | N/A |
| P/E Ratio | $332.14 | ★ $48.15 |
| Revenue Growth | ★ 26.04 | 17.77 |
| 52 Week Low | $18.80 | $7.09 |
| 52 Week High | $27.64 | $17.22 |
| Indicator | PCRX | LXU |
|---|---|---|
| Relative Strength Index (RSI) | 44.78 | 41.05 |
| Support Level | $22.13 | $7.94 |
| Resistance Level | $23.95 | $15.56 |
| Average True Range (ATR) | 0.99 | 0.64 |
| MACD | -0.07 | -0.19 |
| Stochastic Oscillator | 29.05 | 11.85 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
LSB Industries Inc is engaged in the manufacturing and sale of chemical products in the United States. The company manufactures and sells chemical products for the agricultural and industrial sectors. Its products include ammonia, fertilizer grade ammonium nitrate (AN and HDAN), and urea ammonia nitrate (UAN) for agricultural applications; high purity and commercial grade ammonia, sulfuric acids, concentrated, blended, and regular nitric acid, mixed nitrating acids, carbon dioxide, and diesel exhaust fluid for industrial applications; and industrial grade AN (LDAN) and AN solutions for mining applications. Its products are sold through distributors and directly to end customers throughout the United States and other parts of North America.